


## GenBio Announces Provisional Patent for Inflamoxil, a Next-Generation Anti-Inflammatory Therapy

Next-generation therapy aims to redefine treatment for inflammatory conditions

ALISO VIEJO, CA, UNITED STATES, September 4, 2025 /EINPresswire.com/ -- GenBio, a biotechnology company focused on advancing novel therapies for chronic inflammation, today announced the filing of a provisional patent for its latest research innovation, Inflamoxil. This milestone reflects the Company's continued progress in developing safe and effective next-generation treatment modalities that target the underlying mechanisms of chronic inflammation.

Chronic inflammation remains a significant unmet medical need, with patients and healthcare providers



urgently seeking new solutions. Inflamoxil is designed to fill this gap by leveraging specific novel extracts and compounds identified through GenBio's rigorous research and selection process. These compounds demonstrate both safety and efficacy, aligning with GenBio's high standards for therapeutic development.



The value of an idea lies in the using of it"

Thomas A. Edison

A key differentiator for GenBio is its unique ability to identify and target <u>multiple biomarkers</u> simultaneously. This capability positions the Company to address a broad

range of inflammatory ailments across multiple market segments. In particular, Inflamoxil aims to block <u>pro-inflammatory cytokines</u>, a critical driver of chronic inflammation. GenBio is also

exploring the compound's potential to enhance the effectiveness of conventional antibiotics by mitigating antibiotic resistance mechanisms—an approach that could have a farreaching impact on global health.

## About GenBio

GenBio is a biotechnology company dedicated to pioneering nextgeneration therapies that address the root causes of chronic inflammation and related conditions. By combining advanced biomarker identification with innovative therapeutic strategies, GenBio is committed to delivering safe, effective, and transformative treatments that address urgent unmet medical needs across multiple markets.

Forward-Looking Statements Disclaimer

This press release contains forwardlooking statements regarding GenBio's research, development efforts, and future product candidates, including Inflamoxil. These statements are based on current expectations, projections, and assumptions and are subject to



New Trademark Inflamoxil



Provisional Patent Application Filed With USPTO

risks and uncertainties that may cause actual results to differ materially. Forward-looking statements include, but are not limited to, statements regarding potential therapeutic benefits, market opportunities, and development timelines. GenBio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Todd D. Sonoga
GenBio Inc.
+1 9497058021
email us here
Visit us on social media:
LinkedIn
Facebook
X
Other

This press release can be viewed online at: https://www.einpresswire.com/article/845788569

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.